Clinical investigation of epalrestat, aldose reductase inhibitor, on diabetic neuropathy in Japan: Multicenter study

Journal of Diabetes and its Complications

Volumn 10, Issue 3, 1996, Pages 168-172

  Hotta, Nigishi ^a   Sakamoto, Nobuo ^a   Shigeta, Yukio ^a   Kikkawa, Ryuichi ^a   Goto, Yoshio ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; EPALRESTAT;

ADULT; ARTICLE; CLINICAL TRIAL; COLD; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HUMAN; HYPESTHESIA; KIDNEY DISEASE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MOTOR NERVE CONDUCTION; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PAIN; PARESTHESIA; PRIORITY JOURNAL; SENSORY NERVE CONDUCTION; VOMITING;

EID: 0030152978     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/1056-8727(96)00113-4     Document Type: Article

References (9)

1. 1. Terashima H, Hama K, Yamamoto R, Tsuboshima M, Kikkawa R, Hatanaka I, Shigeta Y: Effects of a new aldose reductase inhibitor on various tissues in vitro. J Pharmacol Exp Ther 229:226-230, 1984.
2. 2. Hotta N, Sakamoto N: Aldose reductase inhibitors, in: Alberti KGMM, Krall LP (eds), The Diabetes Annual vol. 5. Amsterdam: Elsevier Science Publishers BV, 1990, pp. 330-361.
3. 3. Steele JW, Faulds D, Goa KL: Epalrestat: A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus. Drugs Aging 3:532-555, 1993.
4. 4. Kikkawa R, Hatanaka I, Yasuda H, Kobayashi N, Shigeta Y, Terashima H, Morimura T, Tsuboshima M: Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene] rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats. Diabetologia 24:290-292, 1983.
5. 5. Hotta, N, Kakuta H, Fukasawa H, Kimura M, Koh N, Iida M, Terashima H, Morimura T, Sakamoto N: Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats. Diabetologia 28:176-180, 1985.
6. 1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats: Comparison with aldose reductase inhibitor ONO 2235. Diabetes 38:832-838, 1989.
7. 7. Hotta N, Sugimura K, Kakuta H, Fukasawa H, Kimura M, Koh N, Matsumae H, Kitoh R, Sakamoto H: Effects of a fructose-rich diet and an aldose reductase inhibitor on the development of diabetic neuropathy in streptozotocin-treated rats, in: Sakamoto N, Kinoshita JH, Kador PF, Hotta N (eds), Polyol Pathway and Its Role in Diabetic Complications. Amsterdam: Elsevier Science Publishers BV, 1988, pp. 505-511.
8. 8. Goto Y, Shigeta Y, Sakamoto N, Kito S, Matsuoka K, Takahashi A, Kikkawa R, Sakuma A: A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy. Igaku-No-Ayumi 1552: 405-416, 1990.
9. 9. Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kito S, Matsuoka K, Takahashi A, Kikkawa R, Sakuma A: A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy. Diabetic Med 10(suppl 2):39S-43S, 1993.